[Blood] Targeting Wnt signaling using a porcupine inhibitor WNT974 alleviates immune suppression in a stem cell–rich, anti-programmed cell death protein 1 (αPD1)-resistant murine glioblastoma model in the orthotopic setting and improves survival in combination with αPD1 treatment by remodeling the tumor microenvironment from protumorigenic to antitumorigenic.

[Molecular Cancer] The authors highlight current research developments regarding acetylcholine in tumor immune regulation, explore its underlying mechanisms and clinical potential, and provide a theoretical basis for developing personalized therapeutic strategies.

[Cell Communication and Signaling] Researchers review the latest advancements in NLRP3 inflammasome research, including its regulatory mechanisms, role in promoting tumor development, and effects in anti-tumor immunotherapy.

[Signal Transduction and Targeted Therapy] By integrating insights from immunology, biotechnology, and translational medicine, scientists propose directions for advancing antigen-specific approaches in the quest for transformative multiple sclerosis therapies.

[Acta Pharmacologica Sinica] Using syngeneic murine models of breast and lung cancers, researchers demonstrated that GCJ-490A alone and in combination with PD-1 antibody inhibits tumor growth by regulating T cells and tumor-associated macrophages.

[MUSC] Medical University of South Carolina (MUSC) geneticist, Dr. Betty Tsao, will lead a five-year project to identify rare mutations associated with childhood-onset systemic lupus erythematosus, or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

[CytoAgents, Inc.] CytoAgents, Inc. announced that it has been awarded a $2.25 million National Institutes of Health (NIH) grant, which will accelerate the development of its lead drug candidate that uses a novel approach to prevent cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome frequently seen with multiple myeloma patients receiving CAR T cell therapy.

[SoftOx Solutions AS] SoftOx Solutions AS announced that it has formally submitted a clinical trial application to the Danish Medicines Agency for approval of its upcoming dose-escalation / Phase ㅑㅑa clinical study in people with cystic fibrosis.

[Journal of Advanced Research] Scientists investigated the molecular features of alcohol and hepatitis B virus on HCC and sought out potential therapeutic strategies.

[Experimental & Molecular Medicine] The role of portal hypertension in cirrhotic ascites was determined through a meta-analysis of portal pressure in cirrhotic patients and animal models.

[Journal of Translational Medicine] A 16-gene integrated model was constructed as a prognostic and predictive tool for HCC immunotherapy.

[Biomaterials Science] Scientists developed a novel nanomedicine comprising tannic acid and a decellularized liver matrix—TD-Nm—to promote recovery from metabolic dysfunction-associated steatotic liver disease.